8-K: NeoGenomics Reports Strong Q4 and Full Year 2024 Results, Revenue Up 12%

NeoGenomics announces a 12% increase in full-year revenue to $661 million, marking the ninth consecutive quarter of double-digit revenue growth.

Summary

• NeoGenomics reported its fourth-quarter and full-year results for the period ended December 31, 2024.
• Fourth-quarter consolidated revenue increased by 11% to $172 million, while full-year consolidated revenue rose by 12% to $661 million.
• The company's fourth-quarter net loss increased by 7% to $15 million, but the full-year net loss decreased by 11% to $79 million.
• Adjusted EBITDA for the fourth quarter increased by 27% to $12 million, and for the full year, it increased by 1,036% to $40 million.
• NGS grew 34% in 2024.
• Average revenue per clinical test increased by 5% to $465 in the fourth quarter.
• The company reaffirmed its full-year 2025 guidance, projecting revenue between $735 million and $745 million and adjusted EBITDA between $55 million and $58 million.
• Cash and cash equivalents and marketable securities totaled $387 million at quarter end.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and improved profitability, supported by reaffirmed guidance. While there are some losses, the overall trend is positive.

Positives

• The company achieved nine consecutive quarters of double-digit revenue growth.
• Adjusted EBITDA showed a substantial increase for both the quarter and the full year.
• NGS revenue experienced significant growth.
• The company has a strong cash position with $387 million in cash, cash equivalents, and marketable securities.
• Gross profit for the fourth quarter of 2024 was $77.3 million, an increase of 14.3% compared to the fourth quarter of 2023.

Negatives

• The net loss for the fourth quarter increased by 7% to $15 million.
• Operating expenses for the fourth quarter of 2024 were $96 million, an increase of $9 million, or 11%, compared to the fourth quarter of 2023.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the company's ability to implement financial and operational initiatives, gain new customers, offer new tests, and integrate acquisitions.

Future Outlook

The company reaffirmed its full-year 2025 guidance, projecting revenue between $735 million and $745 million and adjusted EBITDA between $55 million and $58 million.

Management Comments

• Chris Smith, Chief Executive Officer of NeoGenomics, stated that the business performed well throughout 2024 and achieved nine consecutive quarters of double-digit revenue growth.
• Smith believes the company is well-positioned for long-term sustainable growth through its broad commercial channel, upcoming product launches, and continued focus on disciplined capital deployment.

Industry Context

NeoGenomics operates in the competitive oncology testing services market, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards or competitors.
• Without further information, it's difficult to assess NeoGenomics' performance relative to companies like Exact Sciences, Guardant Health, or Foundation Medicine.

Stakeholder Impact

• Shareholders can expect continued growth and improved profitability.
• Customers will benefit from innovative diagnostic and predictive testing.
• Employees can anticipate a focus on operational efficiency and growth opportunities.

Next Steps

• The company has scheduled a webcast and conference call to discuss its fourth quarter and full year 2024 results on February 18, 2025.
• The company will continue to focus on disciplined capital deployment.

Key Dates

Keywords

NeoGenomics, oncology testing, genetics, diagnostics, revenue, EBITDA, NGS, cancer, financial results